Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
  • A23L33/12—Fatty acids or derivatives thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
  • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7016—Disaccharides, e.g. lactose, lactulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/20—Milk; Whey; Colostrum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• the present invention relates to preventing obesity later in life by administering a particular nutritional composition to non-obese infants with the age below 3 years.
• breast-feeding is the preferred method of feeding infants. However, there are circumstances that make breast-feeding impossible or less desirable. In those cases infant formulae are a good alternative. The composition of modern infant formulae is adapted in such a way that it meets many of the special nutritional requirements of the fast growing and developing infant.
• WO 2005063050 describes a method of increasing lean body mass and reducing fat body mass in infants by administering to an infant, term or preterm, a nutritional formula comprising a source of DHA and ARA.
• WO 2006057551 relates to an infant nutrition comprising at least one protease inhibitor, a process for preparing such an infant nutrition and use of the infant nutrition for the treatment and/or prevention of childhood obesity and secondary disorders resulting from childhood obesity.
• WO 03005836 describes dietary products for infant, child and adult nutrition which possess adequate levels and ratios of medium chain fatty acids and omega- polyunsaturated fatty acids.
• WO 2006069918 describes a method of continuously reducing the circulating level of insulin like growth factor 1 (IGF-I) in the first few months of the life of an infant by administering to the infant a nutritional composition comprising proteins in an amount such that the composition contains less than 2.25 g of protein per 100 kcal.
• IGF-I insulin like growth factor 1
• a main aim of the present invention is to design a nutrition to be administered to an infant which ensures maintenance of normal body composition, growth and development during infancy but which reduces the accumulation of excess body fat mass later in life (i.e. after infancy), preferably during adolescence and/or adulthood.
• mice received specific nutrition (low in LA and low LA/ ALA) early-in-life, while a control group did not receive the specific nutrition. At the later-in-life stage the animal groups received the same diet high in saturated fat.
• the present invention thus relates to a method for preventing the development of obesity of a human infant with an age above 36 months, in other words for preventing development of obesity later-in-life, said method comprising the administration to an infant below 36 months of age a nutritional composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component comprises linoleic acid (LA) and alpha- lino lenic acid (ALA) in a weight ratio of L A/ AL A between 2 and 7; less than 15 wt.% LA based on total fatty acids; and at least 1 wt.% ALA based on total fatty acids.
• LA linoleic acid
• ALA alpha- lino lenic acid
• the invention is also described as the use of a composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component comprises (i) linoleic acid (LA) and alpha- lino lenic acid (ALA) in a weight ratio of LA/ ALA between 2 and 7; (ii) less than 15 wt.% LA based on total fatty acids; and (iii) at least 1 wt.% ALA based on total fatty acids, for the manufacture of a nutritional composition to be administered to a (non-obese) infant with the age below 36 months for the prevention of obesity.
• LA linoleic acid
• ALA alpha- lino lenic acid
• the inventions is preferably described as a composition to be administered to a non-obese human with the age below 36 months, said composition comprising a lipid, protein and digestible carbohydrate component s, wherein the lipid component comprises linoleic acid (LA) and alpha- lino lenic acid (ALA) in a weight ratio of LA/ ALA between 2 and 7; less than 15 wt.% LA based on total fatty acids; and over 1 wt.% ALA based on total fatty acids for preventing the development of a disorder, particularly obesity, when said human has an age above 36 months.
• LA linoleic acid
• ALA alpha- lino lenic acid
• MCFA medium chain fatty acids
• LA is an essential fatty acid, meaning that it cannot be synthesized within the body.
• the present composition comprises a relatively low LA content, it is important that the LA included in the present composition is not converted to energy (by fat oxidation) and therefore not available for anabolic purposes.
• MCFA can suitably be added.
• MCFA are easily mobilized in the bloodstream to provide long-lasting energy, rather than being stored as fat and thereby reduce LA oxidation. Additionally it was surprisingly found that a composition rich in medium chain fatty acids (MCFA) also decreased total body fat mass later-in-life, while having no effect on body composition and growth during infancy. However, MCFA did not specifically reduce visceral fat mass accumulation, but resulted in an overall reduced fat mass content later- in- life. Including MCFA thus prevents LA deficiency and has an advantageous effect on obesity later in life. MCFA are therefore included in the present composition to a limited amount.
• MCFA medium chain fatty acids
• LC-PUFA long chain polyunsaturated fatty acids
• AA arachidonic acid
• n-6 LC-PUFA especially AA
• AA a nutrition rich in n- 3 LC-PUFA
• DHA docosahexaenoic acid
• EPA eicosapentaenoic acid
• n-3 LC-PUFA are also advantageously incorporated in compositions for reducing obesity later-in-life. It is a further aim of the present invention to provide a low LA composition which gives a low insulin response.
• composition comprising a lipid, protein and digestible carbohydrate component wherein the lipid component comprises:
• LA linoleic acid
• ALA alpha- lino lenic acid
• LA/ ALA between 2 and 7;
• composition further comprises at least one selected from the group consisting of :
• MCFA medium chain fatty acids
• LC-PUFA long chain polyunsaturated fatty acids
• LC-PUFA long chain polyunsaturated fatty acids
• LC-PUFA long chain polyunsaturated fatty acids
• LC-PUFA long chain polyunsaturated fatty acids
• LC-PUFA long chain polyunsaturated fatty acids
• LC-PUFA long chain polyunsaturated fatty acids
• LC-PUFA long chain polyunsaturated fatty acids
• n-3 LC-PUFA in a weight ratio below 1.5, from 0.02 to 0.8 wt.% n-6 LC-PUFA based on total fatty acids and at least 0.2 wt.% n-3 LC-PUFA based on total fatty acids, for the manufacture of a nutritional composition to be administered to a (non-obese) infant with an age below 36 months for the prevention of obesity.
• the present composition is administered to a non-obese human infant with the age below 36 months, preferably below 18 months, more preferably below 12 months, even more preferably below 6 months.
• the present composition is administered to a non-overweight human with the age below 36 months, preferably below 18 months, more preferably below 12 months, even more preferably below 6 months of age.
• the absence or presence of obesity and/or overweight in an infant can suitably be determined by a physician.
• a non-obese infant below 36 months of age has gender specific weight-for-length below the 95 th percentile, more preferably below the 85 th percentile. Gender specific weight-for-length percentiles have been published by Center for Disease Control and Prevention (CDC) in 2000.
• the presence or absence of obesity and/or overweight in a human subject above 36 months of age can be easily determined by a physician and/or with the gender specific weight-for-length percentiles published by CDC.
• Health related problems are especially associated with a special form of obesity, namely central obesity.
• the composition is used to prevent central obesity later-in-life.
• the term 'central obesity' refers to a condition with increased visceral fat mass.
• a waist circumference above 102 cm in adult man or above 88 cm in adult women indicates central obesity.
• appropriate cutoffs for age- and sex-dependent waist circumferences can be found in Taylor et al, 2000 Am J Clin Nutr 72:490-495.
• LA refers to linoleic acid (18:2 n6)
• ALA refers to ⁇ -linolenic acid (18:3 n3)
• LC-PUFA refers to long chain polyunsaturated fatty acids and/or acyl chains comprising at least 20 carbon atoms in the fatty acyl chain and with 2 or more unsaturated bonds
• DHA refers to docosahexaenoic acid (22:6, n3)
• EPA refers to eicosapentaenoic acid (20:5 n3)
• ARA refers to arachidonic acid (20:4 n6)
• DPA refers to docosapentaenoic acid (22:5 n3)
• DHGLA refers to dihomogammalinolenic acid (20:3 n6).
• Medium chain fatty acids (MCFA) refer to fatty acids and/or acyl chains with a chain length of 6, 8 or 10 carbon atoms. MCFA may also be
• compositions that have a low LA/ ALA ratio and that are low in LA prevent the occurrence of obesity, especially central obesity.
• a nutritional composition comprising (i) a LA/ALA weight ratio between 2 and 7 and (ii) a low LA content ( ⁇ 15 wt.% based on total fatty acids), resulted in a decreased obesity later in life.
• the present composition comprises lipid.
• LA should be present in a sufficient amount in order to promote a healthy growth and development, yet in an amount as low as possible to prevent occurrence of obesity later in life.
• the composition therefore comprises less than 15 wt.% LA based on total fatty acids, preferably between 5 and
• the present composition preferably comprises 1.5 to 5 wt.% LA.
• the LA content is preferably between 0.2 and 0.55 g LA per 100 ml of the liquid composition.
• the LA preferably provides between 4 to 8% of total calories in the present composition.
• the present composition therefore comprises at least 1.0 wt.% based on total fatty acids.
• the composition comprises at least 1.6 wt.% ALA based on total fatty acids, more preferably at least 2.0 wt.%.
• the composition comprises less than 10 wt.% ALA, more preferably less than 5.0 wt.% based on total fatty acids.
• the present composition preferably comprises at least 0.10 wt.% ALA, preferably between 0.10 and 0.8 wt.% ALA.
• the ALA content is preferably at least 30 mg ALA per 100 ml of the liquid composition, preferably between 50 and 150 mg ALA per 100 ml.
• the weight ratio LA/ALA should be well balanced in order to prevent obesity, especially central obesity, while at the same time ensuring a normal growth and development. The proper ratio was found by the present inventors.
• the present composition comprises a weight ratio of LA/ ALA between 2 and 7, more preferably between 3 and 6, even more preferably between 4 and 5.5, even more preferably between 4 and 5.
• the lipid component comprises less than 15 wt.% LA based on total fatty acids and a LA/ ALA ratio of 2 to 7.
• n-3 LC PUFA was found to reduce both obesity and central obesity later- in-life and MCFA were found to reduce only general obesity later-in-life only. This finding further enables the development of an optimal composition, which preferably comprises MCFA, but not in excessive amounts, i.e. between 3 and 50 wt.% based on total weight of fatty acids and/or LC-PUFA including n-6 LC PUFA but with a low n-6 LC-PUFA/n-3 LC-PUFA ratio .
• MCFA Medium chain fatty acids
• LA is an essential fatty acid, meaning that it cannot be synthesized within the body.
• the present composition comprises a relatively low LA content, it is important that the LA included in the present composition is not converted to energy (by fat oxidation) and therefore not available for anabolic purposes.
• MCFA can suitably be added. MCFA are easily mobilized in the bloodstream to provide energy, rather than being stored as fat and thereby reduce LA oxidation.
• the present composition preferably comprises at least 3 wt.% MCFA based on total fatty acids, more preferably at least 10 wt.%, even more preferably 15 wt.%.
• the present inventors found that MCFA reduces body fat deposition with no preference for central fat mass. Therefore, the present low LA and low LA/ ALA composition advantageously comprises less than 50 wt.% MCFA based on total fatty acids, more preferably less than 40 wt.%, even more preferably less than 25 wt.%.
• the present composition comprises LC-PUFA.
• the present inventors found that LC-PUFA reduce obesity later in life, more preferably central obesity. More preferably, the present composition comprises n-3 LC-PUFA, even more preferably EPA, DPA and/or DHA, even more preferably DHA. It was found that these n-3 LC- PUFA decrease obesity.
• the content of n-3 LC-PUFA in the present composition preferably does not exceed 15 wt.% of the total fatty acid content, preferably does not exceed 10 wt.%, even more preferably does not exceed 5 wt.%.
• the present composition comprises at least 0.2 wt.%, preferably at least 0.5 wt.%, more preferably at least 0.75 wt.% n-3 LC-PUFA of the total fatty acid content.
• the EPA content preferably does not exceed 5 wt.% of the total fatty acid, more preferably does not exceed 1 wt.%, but is preferably at least 0.025 wt.%, more preferably at least 0.05 wt.% of the total fatty acid.
• the DHA content preferably does not exceed 5 wt.%, more preferably does not exceed 1 wt.%, but is preferably at least 0.1 wt.% of the total fatty acid.
• the DPA content preferably does not exceed 1 wt.%, more preferably does not exceed 0.5 wt.% of the total fatty acid content, but is preferably at least 0.01 wt.% of the total fatty acid.
• n-3 LC-PUFA single cell oil preferably algal oil, fungal oil and/or microbial oil is used, since these oil sources have a low EPA/DHA ratio, which results in an increased anti-obesity effect.
• the present composition comprises fish oil (more preferably tuna oil). Fish oil has a higher EPA concentration which is advantageous since EPA is precursor of eicosanoids which have an additional anti-obesity effect.
• AA arachidonic acid
• LA as its precursor, counteracts the group of n-3 fatty acids, especially DHA and EPA and ALA as their precursor
• the present composition comprises relatively low amounts of AA.
• the n-6 LC-PUFA content preferably does not exceed 5 wt.%, more preferably does not exceed 0.8 wt.%, more preferably does not exceed 0.75 wt.%, even more preferably does not exceed 0.5 wt.% based on total fatty acids. Since AA is important in infants for optimal functional membranes, especially membranes of neurological tissues, the amount of n-6 LC-PUFA is preferably at least 0.02 wt.%, more preferably at least 0.05 wt.%, even more preferably at least 0.1 wt.% based on total fatty acids, more preferably at least 0.25 wt.%.
• the present composition preferably contains less than 1 wt.% AA based on total fatty acids.
• AA is advantageous in a composition low in LA since it remedies LA deficiency.
• the presence of, preferably low amounts, of AA is beneficial in nutrition to be administered to infants below the age of 6 months, since for these infants the infant formulae is generally the only source of nutrition.
• the weight ratio n-6 LC-PUFA / n-3 LC-PUFA in the present infant nutrition is preferably low in order to prevent obesity later in life.
• the composition comprises a weight ratio of n-6 LC-PUFA / n-3 LC-PUFA below 1.5, more preferably below 1.0, even more preferably below 0.6.
• LA, ALA, MCFA and/or LC-PUFA are preferably provided as free fatty acids, in triglyceride form, in diglyceride form, in monoglyceride form, in phospholipid form, or as a mixture of one of more of the above.
• the present composition contains LC-PUFA in triglyceride and/or phospholipid form, even more preferably phospholipid form since LC-PUFA in phospholipid form are better incorporated into membranes.
• the present composition contain MCFA in triglyceride form
• Table 1 gives preferred characteristics of the lipid component of the present composition
• the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil (flaxseed oil), rape seed oil
• the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil, rapeseed oil, coconut oil, high oleic sunflower oil, butter oil and marine oil.
• Phospholipids cholesterol and sphingolipids
• LA is an essential fatty acid and n-6 LC-PUFA are important membrane components (including in neurological tissue membranes)
• the small amount of LA and optionally n-6 LC-PUFA present in the composition of the invention are preferably incorporated into neurological cell membranes as efficiently as possible. This can be achieved by providing lipidic membrane components, including cholesterol, phospholipids and/or sphingolipids in the present low LA composition. The presence of these components increases the incorporation of PUFA, including LA and n-6 LC-PUFA in membranes, thereby preventing oxidation.
• phospholipids as used in the present invention particularly refers to glycerophospho lipids.
• Glycerophospho lipids are a class of lipids formed from fatty acids esterified to the hydroxyl groups on carbon- 1 and carbon-2 of the backbone glycerol moiety and a negatively-charged phosphate group attached to carbon-3 of the glycerol via an ester bond, and optionally a choline group (in case of phosphatidylcholine), a serine group (in case of phosphatidylserine), an ethanolamine group (in case of phosphatidylethanolamine), an inositol group (in case of phosphatidylinositol) or a glycerol group (in case of phosphatidylglycerol) attached to the phosphate group.
• a choline group in case of phosphatidylcholine
• serine group in case of phosphatidylserine
• the present composition contains phosphatidylcholine (PC), phosphatidylserine, phosphatidylinositol and/or phosphatidylethanolamine, more preferably at least phosphatidylcholine.
• PC phosphatidylcholine
• phosphatidylserine phosphatidylserine
• phosphatidylinositol phosphatidylethanolamine
• a preferred source for phospholipids, particularly PC, is soy lecithin, egg lipid, and/or buttermilk fat.
• the present composition preferably comprises soy lecithin, egg lipid and/or buttermilk fat, more preferably soy lecithin and/or buttermilk fat.
• the present composition comprises 0.5 to 20 wt.% phospholipids based on total lipid, more preferably 1 to 10 wt.%, even more preferably 4 to 8 wt%.
• oral administration of a composition comprising phospholipids and/or sphingo lipids and/or cholesterol has the further advantage that it decreases the post-prandial insulin response (see example 2).
• the present composition for infants aimed to decrease obesity later in life preferably comprises phospholipids, sphingo lipids and/or cholesterol, more preferably phospholipids.
• the present composition comprises 0.5 to 20 wt.% sphingolipids based on total lipid, more preferably 1 to 10 wt.%, even more preferably 4 to 8 wt.%.
• the term sphingolipids as in the present invention particularly refers to glycolipids with an amino alcohol sphingosine.
• the sphingosine backbone is 0-linked to a (usually) charged headgroup such as ethanolamine, serine or choline backbone.
• the backbone is also amide linked to a fatty acyl group.
• Sphingolipids include sphingomyelin, ceramides, and glycosphingolipids.
• the present composition contains sphingomyelin and/or glycosphingolipids.
• Glycosphingolipids are ceramides with one or more sugar residues joined in a ⁇ -glycosidic linkage at the 1-hydroxyl position.
• Glycosphingolipids may be further subdivided into cerebrosides, globosides and gangliosides. Cerebrosides have a single glucose or galactose at the 1 -hydroxy position, while gangliosides have at least three sugars, one of which must be sialic acid.
• Sphingomyelins have a phosphorylcholine or phosphoroethanolamine molecule esterified to the 1 -hydroxy group of a ceramide.
• the present composition contains gangliosides.
• the composition comprises sphingolipids, more preferably sphingomyelin and/or gangliosides.
• the present composition comprises at least one ganglioside selected from the group consisting of GM3 and GD3.
• the present composition comprises 0.5 to 20 wt.% (sphingolipids plus phospholipids) based on total lipid, more preferably 1 to 10 wt.%, even more preferably 4 to 8 wt.%. Dietary cholesterol modulates lipid metabolism by the stimulation of chain elongation of the fatty acyl chains (phospholipids, free fatty acids; diglycerides and triglycerides).
• the present invention also provides the use of a composition comprising a lipid, protein, digestible carbohydrate and cholesterol for the manufacture of a nutritional composition to be administered to an infant with the age below 36 months for the prevention of cardiovascular disease, atherosclerosis and/or high blood cholesterol levels later in life.
• This nutritional composition preferably has at least part of the nutrient requirement described in the present application, e.g. advantageously includes the non-digestible oligosaccharide, lactose and/or lipid component as described herein.
• Preferred sources of cholesterol are milk fat, buttermilk fat, butterserum fat and egg lipids.
• the present composition preferably comprises buttermilk fat, butterserum fat and/or egg lipids.
• the present composition preferably comprises at least 0.005 wt.% cholesterol based on total fat, more preferably at least 0.01 wt.%, more preferably at least 0.05 wt.%., even more preferably at least 0.1 wt.%.
• the amount of cholesterol does not exceed 10 wt.% based on total lipid, more preferably does not exceed 5 wt.%, even more preferably does not exceed 1 wt.% of total lipid.
• Most preferably the amount of cholesterol is 0.5 to 0.7 wt.% based on total lipid.
• the amount of cholesterol does not exceed 1 wt.% based on total fat, more preferably does not exceed 0.5 wt.%.
• Uridine and choline are examples of Uridine and choline.
• the present low LA composition comprises a source of uridine and choline.
• enhanced membrane synthesis is preferably achieved by providing the two main precursors for phosphatidyl choline or other major membrane phospholipids in brain, namely a source of uridine and choline.
• Uridine is metabolized to cytidine and subsequently phosphorylated to CTP; choline is metabolized to phosphocholine.
• CTP and phosphocholine result in CDP-choline formation, a key step in phospholipid biosynthesis pathway.
• the combination of a source of uridine and choline stimulate phospholipid biosynthesis.
• the increase of phospholipid synthesis caused by uridine and choline supplementation also enhances the incorporation of arachidonic acids and other LC-PUFA into the mayor phospholipids in the brain, which makes it particularly suitable for counteracting side effects of the present low LA composition.
• the composition comprises a source of uridine and choline.
• Choline is preferably added as choline chloride.
• the present composition preferably comprises choline chloride.
• the present composition preferably comprises at least 0.035 wt.% choline based on dry weight of the composition, more preferably at least 0.045 wt.%.
• the present composition comprises no more than 1 wt.% choline based on total dry weight or the present composition, more preferably below 0.5 wt.%, even more preferably below 0.1 wt.%.
• the presence of choline has the further advantage that it oxidizes fat, results in an increase of lean body mass and enhances the fat clearance of blood into cells.
• the composition of the present invention preferably comprises choline.
• the present composition comprises uridine in the form of a nucleotide, nucleoside and/or base.
• the composition comprises 0.001 to 0.1 wt.% uridine based on dry weight of the present composition, more preferably 0.002 to 0.05 wt.%, most preferably 0.002 to 0.025 wt.%.
• the composition comprises uridine in nucleotide form.
• the uridine is preferably in the nucleotide monophosphate, diphosphate or triphosphate form, more preferably in nucleotide monophosphate form.
• the uridine nucleotides can be monomeric, dimeric or polymeric (including RNA).
• the nucleotides preferably are present as a free acid or in the form of a salt, more preferably monosodium salt.
• the present composition comprises uridine 5'-monophospate and/or salts thereof (collectively abbreviated to UMP), in particular monosodium salts thereof.
• the composition comprises 0.001 to 0.1 wt.% UMP based on dry weight of the present composition, more preferably 0.002 to 0.05 wt.%, most preferably 0.002 to 0.025 wt.%.
• UMP is preferably be added to the composition in a mixture of nucleotides.
• the present composition contains yeast RNA as a source of UMP.
• the composition comprises UMP and choline.
• the composition comprises a source of uridine, choline and phospholipids.
• the composition comprises UMP, choline and phospholipids. This combination even further stimulates membrane formation and is therefore particularly suitable for inclusion in the present low LA composition.
• high blood insulin levels stimulate glucose uptake in adipose tissue, resulting in an increased adipose tissue mass.
• the high insulin levels contribute to increased proliferation of adipocytes, at least partly due to the increased glucose uptake, and thereby in an increased chance of obesity later in life.
• the present composition therefore preferably maintains low insulin levels. It was found that non-digestible oligosaccharides (NDO) that can be fermented (particularly galacto-oligosaccharides) have a blood insulin tempering effect, and consequently contribute to a reduced change on obesity later- in- life.
• NDO non-digestible oligosaccharides
• the present composition comprises non-digestible oligosaccharides.
• Fermentation of these non-digestible oligosaccharides preferably galacto- oligosaccharides, further results in the formation of intestinal acetate which is taken up and will enter the circulation and the liver, thereby serving advantageously as a lipid elongation precursor and/or advantageously stimulating the conversion of LA to AA.
• the present composition preferably comprises the present lipid component and a non-digestible oligosaccharide which can be fermented.
• the combination of the present lipid component and the non-digestible oligosaccharides synergistically reduces the obesity later in life.
• the present composition comprises non- digestible oligosaccharides with a degree of polymerisation (DP) between 2 and 60.
• DP degree of polymerisation
• the composition preferably prevents the onset of insulin resistance.
• the non- digestible oligosaccharide is preferably selected from the group consisting of fructo- oligosaccharides (including inulin), galacto-oligosaccharides (including transgalacto- oligosaccharides), gluco-oligosaccharides (including gentio-, nigero- and cyclodextrin-oligosaccharides), arabino-oligosaccharides, mannan-oligosaccharides, xylo-oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides.
• the present composition comprises fructo-oligosaccharides, galacto-oligosaccharides and/or galacturonic acid oligosaccharides, more preferably galacto-oligosaccharides, most preferably transgalacto-oligosaccharides.
• the composition comprises a mixture of transgalacto-oligosaccharides and fructo-oligosaccharides.
• the present composition comprises galacto-oligosaccharides with a DP of 2-10 and/or fructo-oligosaccharides with a DP of 2-60.
• the galacto-oligosaccharide is preferably selected from the group consisting of transgalacto-oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT.
• the present method comprises the administration of transgalacto-oligosaccharides ([galactose] n -glucose; wherein n is an integer between 1 and 60, i.e. 2, 3, 4, 5, 6, ...., 59 ,60; preferably n is selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10).
• Transgalacto-oligosaccharides are for example sold under the trademark VivinalTM (Borculo Domo Ingredients, Netherlands).
• the saccharides of the transgalacto-oligosaccharides are ⁇ - linked.
• Fructo-oligosaccharide is a NDO comprising a chain of ⁇ linked fructose units with a DP or average DP of 2 to 250, more preferably 10 to 100.
• Fructo- oligosaccharide includes inulin, levan and/or a mixed type of polyfructan. An especially preferred fructo-oligosaccharide is inulin.
• Fructo-oligosaccharide suitable for use in the compositions is also already commercially available, e.g.
• Uronic acid oligosaccharides are preferably obtained from pectin degradation.
• the present composition preferably comprises a pectin degradation product with a DP between 2 and 100.
• the pectin degradation product is prepared from apple pectin, beet pectin and/or citrus pectin.
• the composition comprises transgalacto-oligosaccharide, fructo-oligosaccharide and a pectin degradation product.
• the weight ratio transgalacto-oligosaccharide : fructo- oligosaccharide : pectin degradation product is preferably 20 to 2 : 1 : 1 to 3, more preferably 12 to 7 : 1 : 1 to 2.
• the present composition preferably comprises in addition to the present lipid component, non-digestible oligosaccharides and/or lactose.
• the present composition preferably comprises a digestible carbohydrate component, wherein at least 35 wt.%, more preferably at least 50 wt.%, more preferably at least 75 wt.%, even more preferably at least 90 wt.%, most preferably at least 95 wt.% is lactose.
• the present composition preferably comprises at least 25 grams lactose per 100 gram dry weight of the present composition, preferably at least 40 grams lactose/100 gram.
• the composition comprises hydrolyzed casein and/or hydrolyzed whey protein. It was found that administration of a composition wherein the protein comprises hydrolyzed casein and hydrolyzed whey results in reduced post-prandial levels of both insulin and glucose compared to the administration of a composition comprising intact casein and intact whey protein. Increased levels of both insulin and glucose indicate a form of insulin resistance in formula fed infants, which is believed contribute to the development of obesity later- in- life.
• the present composition preferably comprises at least 25 wt.% peptides with a chain length of 2 to 30 amino acids based on dry weight of protein.
• the amount of peptides with a chain length between 2 and 30 amino acids can for example be determined as described by de Freitas et al, 1993, J. Agric. Food Chem. 41:1432-1438.
• the present composition preferably comprises casein hydro lysate and/or whey protein hydro lysate, more preferably casein hydro lysate and whey protein hydro lysate because the amino acid composition of bovine casein is more similar to the amino acid composition found in human milk protein and whey protein is easier to digest and found in greater ratios in human milk.
• the composition preferably comprises at least 50 wt.%, preferably at least 80 wt.%, most preferably about 100 wt.% of a protein hydrolysate, based on total weight of the protein.
• the present composition preferably comprises a protein with a degree of hydrolysis of the protein between 5 and 25%, more preferably between 7.5 and 21%, most preferably between 10 and 20%.
• the degree of hydrolysis is defined as the percentage of peptide bonds which have been broken down by enzymatic hydrolysis, with 100% being the total potential peptide bonds present.
• Casein is advantageously present since it increases the gastric emptying times by forming a curd in the stomach, thereby increasing satiety.
• the present composition preferably comprises casein.
• the composition when the composition is in liquid form, e.g. as a ready-to-drink liquid, the composition preferably comprises at least 0.5 g casein per 100 ml, preferably between 0.5 and 5 gram casein per 100 ml.
• the composition comprises at least 4 wt.% casein based on dry weight.
• the casein is intact and/or non- hydro lyzed.
• the composition comprises calcium.
• Increased dietary calcium decreases the intracellular calcium concentration in adipocytes and this may in decrease adipocytes late stage differentiation and lipid filling.
• the calcium is added with as counter anion carbonate, hydroxide, chloride, phosphate, lactate, gluconate, and/or citrate.
• the composition comprises at least 0.1 wt.% calcium based on dry weight of the composition, preferably at least 0.25 wt.% most preferably at least 0.4 wt.%.
• the composition comprises less than 5 wt.% calcium based on dry weight of the composition, preferably less than 2 wt.%, more preferably less than 1 wt.%.
• the present composition is particularly suitable for providing the daily nutritional requirements to an infant with the age below 36 months, particularly an infant with the age below 24 months, even more preferably an infant with the age below 18 months, most preferably below 12 months of age.
• the present composition comprises a lipid, protein and digestible carbohydrate component wherein the lipid component provides preferably 35 to 55% of the total calories, the protein component preferably provides 5 to 15% of the total calories and the digestible carbohydrate component preferably provides 30 to 60% of the total calories.
• the present composition comprises a lipid component providing 40 to 50% of the total calories, a protein component provides 6 to 12% of the total calories and a digestible carbohydrate component provides 40 to 50% of the total calories.
• the composition preferably comprises 2.1 to 6.5 g lipid per 100 ml, more preferably 3.0 to 4.0 g perl 00 ml. Based on dry weight the present composition preferably comprises 12.5 to 40 wt.% lipid, more preferably 19 to 30 wt.%.
• the amount of saturated fatty acids is preferably below 58 wt.% based on total fatty acids, more preferably below 45 wt.%.
• the concentration of monounsaturated fatty acids preferably ranges from 17 to 60% based on weight of total fatty acids.
• the present composition is not human breast milk.
• the present composition preferably comprises (i) vegetable lipid and/or animal (non-human) fat; and/or (ii) vegetable protein and/or animal (non-human) milk protein.
• animal milk protein are whey protein from cow's milk and protein from goat milk.
• the present composition preferably does not comprise a proteinase inhibitor, preferably not a trypsin inhibitor, chymotrypsin inhibitor or elastase inhibitor.
• the present composition is not human milk.
• the present composition preferably comprises at least 50 wt.% protein derived from non-human milk based on total protein, more preferably at least 90 wt.%.
• the present composition comprises at least 50 wt.% cow's milk derived protein based on total protein, more preferably at least 90 wt.%.
• the present composition comprises acid whey and/or sweet whey with a reduced concentration of glycomacropeptide.
• the present composition comprises protein derived from ⁇ -casein and/or ⁇ -lactalbumin.
• the present composition preferably comprises casein and whey proteins in a weight ratio casein:whey of 10:90 to 90:10, more preferably 20:80 to 80:20.
• protein refers to the sum of proteins, peptides and free amino acids.
• the present composition preferably contains 1.5 to 3.0 g protein/100 kcal, preferably between and 1.8 and 2.25 g/100 kcal, even more preferably between and 1.8 and 2.0 g/100 kcal.
• the present composition is preferably administered in liquid form.
• the composition preferably comprises 50 to 200 kcal/100 ml liquid, more preferably 60 to 90 kcal/100 ml liquid, even more preferably 60 to 75 kcal/100 ml liquid.
• This caloric density ensures an optimal ratio between water and calorie consumption.
• the osmolarity of the present composition is preferably between 150 and 420 mOsmol/1, more preferably 260 to 320 mOsmol/1.
• the low osmolarity aims to reduce the gastrointestinal stress. Stress can induce obesity.
• the composition is in a liquid form, with a viscosity below 35 cps as measured in a Brookfield viscometer at 20°C at a shear rate of 100 s "1 .
• the composition is in a powdered from, which can be reconstituted with water to form a liquid, or in a liquid concentrate form, which should be diluted with water.
• the preferred volume administered on a daily basis is in the range of about 80 to 2500 ml, more preferably about 450 to 1000 ml per day.
• Adipocytes including visceral adipocytes, proliferate during the first 36 months of life as well as (more limited) in puberty.
• the amount of adipocytes is an important determinant in the degree of obesity later- in- life.
• the present composition is administered to the infant during the first 3 years of life. It was found that there is a predominance of proliferation of (visceral) adipocytes in the first 12 months of life (with an optimum in perinatal adipocyte proliferation). Hence, it is particularly preferred that the present composition is administered to the infant in this period of life.
• the present composition is therefore advantageously administered to a human of 0-24 months, more preferably to a human of 0-18 months, most preferably to a human of 0-12 months.
• the present invention particularly aims to prevent obesity later- in-life and is preferably not an obesity treatment.
• the present composition is preferably administered to an infant not suffering from obesity or childhood obesity, particularly a non-obese infant more preferably an infant that does not suffer from overweight.
• the present composition is preferably administered orally to the infant.
• the present invention also aims to prevent the occurrence of obesity at the age above
• composition is used to prevent obesity, more preferably central obesity
• Example 1 Programming effect of dietary lipid on adult fat tissue Offspring of C57/BL6 dams was standardized on postnatal day 2 to nests of 6 pups (4M and 2F) per dam. Dams were fed the experimental diet from day 2 onward until weaning. The lipid composition of the mouse milk reflects the fat composition of the diet. After weaning the male mice were housed in pairs and the experimental diet was continued until day 42 when all pups were fed the same diet containing lard and extra cholesterol (1%).
• the experimental diets that were used were: 1) LC-PUFA diet (tuna fish oil); 2) Low LA, low LA/ALA diet (butter oil; low in canola oil, high in Trisun 80, no palm oil); 3) MCFA diet; 4) control diet (similar amounts of canola oil, coconut oil and palm oil).
• the fatty acid composition of the diets is presented in Table 2.
• all mice switched to a "cafeteria diet" comprising 10 wt.% lipid (3 wt.% lard fat and lwt.% cholesterol) until day 98.
• the mice were weighed twice a week.
• the food intake was determined once a week during the entire experiment.
• Table 3 Fat % development of total body mass in time and ratio's of subcutaneous (epididymal) and central (renal) fat.
• Example 2 Phospholipids beneficially affect insulin sensitivity
• Nutritional compositions A complete infant formula with extra added phospholipids
• the experimental composition comprised about 1.4 wt.% sphingomyelin based on total lipid and about 4 wt.% cholesterol based on total lipid.
• the amount of sphingomyelin and cholesterol was negligible in the control formula.
• results The area under the curve (AUC) of insulin was lower in rats fed phospholipd containing formula than in rats fed with standard formula. (Table 4).
• Administration of a phospholipid, sphingolipid and/or cholesterol comprising formula resulted in post-prandial insulin levels and kinetics more similar to those previously observed with human milk. Decreased levels of insulin indicate increased insulin sensitivity, which is believed contribute to the prevention of obesity, especially central obesity, later-in-life.
• Table 4 Effects of phospholipids on post-prandial area under the curve of insulin. Effect Standard Phospholipids Human milk
• Insulin 9.8 ⁇ 1.4 9.5 ⁇ 1.0
• Insulin (pM*15min) 14.8 ⁇ 2.1 13.8 ⁇ 1.6
• Infant nutrition comprising a lipid component providing 48% of the total calories, a protein component providing 8% of the total calories and a digestible carbohydrate component providing 44% of the total calories; (i) the lipid component comprising based on total fatty acids: 14 wt.% LA; 2.6 wt.% ALA, 3.7 wt.% MCFA; 0.2 wt.% DHA, 0.05 wt.% EPA; 0.02 wt.% DPA, 0.35 wt.% AA, 0.03 wt.% DHGLA.
• the composition comprises about 0.75 wt.% soy phospholipids and > 0.005 wt.% cholesterol, (ii) the carbohydrate component comprising 50.9 gram lactose/100 gram powder; 5.22 g galacto-oligosaccharides with DP 2-6 and 0.58 g fructo- oligosaccharides with DP 7-60; (ii) the protein component comprising cow milk protein, including casein. Furthermore the composition comprises 73 mg choline and 5.6 mg UMP per 100 g dry weight. The composition comprises 364 mg calcium per 100 g dry weight. The composition comprises vitamins and minerals according to EU guidelines. The label of the package of this infant nutrition indicates that the nutrition prevents the development of obesity.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Nutrition Science (AREA)
• Molecular Biology (AREA)
• Food Science & Technology (AREA)
• Mycology (AREA)
• Diabetes (AREA)
• Polymers & Plastics (AREA)
• Zoology (AREA)
• Immunology (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Virology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Marine Sciences & Fisheries (AREA)
• Biotechnology (AREA)
• Cell Biology (AREA)
• Developmental Biology & Embryology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pediatric Medicine (AREA)
• Cardiology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Neurology (AREA)
• Urology & Nephrology (AREA)

Priority Applications (6)

Applications Claiming Priority (4)

Publications (2)

Family

ID=37964343

Family Applications (3)

Family Applications Before (1)

Family Applications After (1)

Country Status (14)

Cited By (29)

Families Citing this family (46)

Family Cites Families (37)

• 2006
  • 2006-12-22 WO PCT/NL2006/050329 patent/WO2007073193A2/en not_active Ceased
  • 2006-12-22 RU RU2008130365/13A patent/RU2444210C2/ru not_active IP Right Cessation
  • 2006-12-22 RU RU2008130370/13A patent/RU2417712C2/ru active
  • 2006-12-22 EP EP06824323A patent/EP1962617A2/en not_active Withdrawn
  • 2006-12-22 HU HUE06824326A patent/HUE026440T2/en unknown
  • 2006-12-22 MY MYPI20082246A patent/MY149164A/en unknown
  • 2006-12-22 CA CA002634895A patent/CA2634895A1/en not_active Abandoned
  • 2006-12-22 BR BRPI0620465-1A patent/BRPI0620465A2/pt not_active Application Discontinuation
  • 2006-12-22 RU RU2008130367/15A patent/RU2414905C2/ru not_active IP Right Cessation
  • 2006-12-22 BR BRPI0620466-0A patent/BRPI0620466A2/pt not_active Application Discontinuation
  • 2006-12-22 US US12/158,931 patent/US20090186803A1/en not_active Abandoned
  • 2006-12-22 EP EP11150747A patent/EP2305049A1/en not_active Withdrawn
  • 2006-12-22 EP EP06824326.0A patent/EP1962823B1/en not_active Revoked
  • 2006-12-22 AU AU2006327995A patent/AU2006327995B2/en not_active Ceased
  • 2006-12-22 WO PCT/NL2006/050328 patent/WO2007073192A2/en not_active Ceased
  • 2006-12-22 AU AU2006327996A patent/AU2006327996B2/en active Active
  • 2006-12-22 JP JP2008547136A patent/JP2009521214A/ja active Pending
  • 2006-12-22 BR BRPI0620451-1A patent/BRPI0620451A2/pt not_active IP Right Cessation
  • 2006-12-22 EP EP06824324.5A patent/EP1973424B1/en active Active
  • 2006-12-22 PL PL06824326T patent/PL1962823T3/pl unknown
  • 2006-12-22 AU AU2006327997A patent/AU2006327997B2/en active Active
  • 2006-12-22 CA CA002634693A patent/CA2634693A1/en not_active Abandoned
  • 2006-12-22 ES ES06824326.0T patent/ES2537080T3/es active Active
  • 2006-12-22 CA CA002634117A patent/CA2634117A1/en not_active Abandoned
  • 2006-12-22 CN CN201310014398.XA patent/CN103054048B/zh active Active
  • 2006-12-22 WO PCT/NL2006/050331 patent/WO2007073194A2/en not_active Ceased
  • 2006-12-22 PT PT68243260T patent/PT1962823E/pt unknown
  • 2006-12-22 US US12/158,857 patent/US20110136732A1/en not_active Abandoned
  • 2006-12-23 MY MYPI20082287A patent/MY162091A/en unknown
• 2012
  • 2012-01-24 US US13/357,109 patent/US8871218B2/en active Active
• 2016
  • 2016-03-01 US US15/057,324 patent/US20160175393A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events